Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12192094 | 0.95 | CYP3A4 (0.60) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL12922282 | 0.92 | HTR2A (0.57) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL12192092 | 0.87 | HTR2A (0.56) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL12922286 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL12192090 | 0.81 | CYP3A4 (0.53) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL15109357 | 0.78 | CYP1A2 (0.62) | CYP3A4CYP2C19HTR2ACYP2C9KCNH2 | |
| SCHEMBL15109267 | 0.77 | CYP3A4 (0.59) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL15109375 | 0.76 | CYP3A4 (0.70) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL15109295 | 0.76 | CYP3A4 (0.70) | CYP3A4CYP2C19HTR2ACTSGMAOA | |
| SCHEMBL15109351 | 0.76 | CYP3A4 (0.66) | CYP3A4CYP2C19HTR2ACTSGMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | CYP3A4 1785/4885CYP2C19 2103/4885HTR2A 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.